ubiquitin protein ligase E3BGenealiases: BPIDS · KOS
Q-omics provides the consensus-scored UBE3B profile across patient tissues and cancer cell-line models. UBE3B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, UBE3B is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, UBE3B RNA expression shows 20,979 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, LIHC, and UVM as cancer lineages where UBE3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE3B survival associations across molecular data types. UBE3B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE3B RNA expression–survival associations across cancer types. High UBE3B expression shows unfavorable associations in MESO, OV, LGG and LIHC, but favorable associations in KIRC and UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for UBE3B RNA expression.
This table summarizes UBE3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 7. The strongest signals are observed in LIHC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for UBE3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE3B shows lower tumor expression in THCA and COAD and higher tumor expression in LIHC, HNSC, BRCA and CHOL. The LIHC box plot shows higher UBE3B RNA expression in tumor versus normal tissue (log2 FC = +0.965, t-test p < 0.001).
This table shows molecular features associated with UBE3B in patient tissues and cancer cell lines. In patient samples, UBE3B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, UBE3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
